Is there still a need to reduce myocardial infarct size in patients with ST-segment elevation myocardial infarction?
Ischaemic heart disease (IHD) remains the leading cause of death and disability in Europe and worldwide. A major cause of morbidity and mortality in IHD patients is an acute ST-segment elevation myocardial infarction (STEMI), which despite prompt reperfusion by primary percutaneous coronary intervention (PPCI) has significant mortality (7% death at 1 year) and morbidity (22% prolonged or new hospitalization for heart failure at 1 year) in patients with large infarcts.
1 When high-risk STEMI patients presenting with cardiogenic shock are not excluded, mortality at 1 year is even higher, at 12% after 1 year. 2 As such, there remains an urgent need to discover novel therapies which can be given prior to or at the time of PPCI to reduce myocardial infarct (MI) size in order to preserve left ventricular (LV) systolic function, prevent the onset of heart failure, and improve survival in reperfused STEMI patients. In patients presenting with STEMI, rapid access to the emergency medical services and timely reperfusion by PPCI minimize the total ischaemic time, a major determinant of MI size. Although myocardial reperfusion is essential to salvage myocardium following a STEMI, the process of restoring coronary blood flow to the ischaemic tissue can, in itself, induce myocardial injury and cardiomyocyte death, a phenomenon which is known as 'myocardial reperfusion injury'. 3, 4 Crucially, there is currently no effective therapy for reducing myocardial reperfusion injury in STEMI patients, and therefore, it remains a valid target for cardioprotection. However, the search for an effective therapy capable of targeting myocardial reperfusion injury and reducing MI size has been quite challenging, with a large number of failures to translate novel cardioprotective therapies into the clinical setting. 5, 6 In this consensus article, we highlight the importance of myocardial reperfusion injury as a viable target for cardioprotection and discuss the potential reasons underlying the neutral results of recent clinical cardioprotection trials and explore the future possibilities for reducing MI size and improving clinical outcomes in patients with IHD.
Why has it been so difficult to prevent myocardial reperfusion injury in patients with ST-segment elevation myocardial infarction?
One major factor is an incomplete understanding of the mechanisms underlying myocardial reperfusion injury, with variable reperfusion times, multiple pathophysiological factors (calcium overload,
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oxidative stress, inflammation, and mitochondrial dysfunction), and multiple players (cardiomyocytes, microvasculature, inflammatory cells, and platelets), making it a complex phenomenon to target effectively. 4, 7, 8 There is general agreement that a large part of the cell death caused by myocardial reperfusion injury occurs during the first few minutes of reperfusion, and that early treatment is required to prevent it. 4, 7 The most important aspect of reperfusion injury is cardiomyocyte cell death, which depends mainly on phenomena occurring within cardiomyocytes themselves, as it is possible to recapitulate reperfusion injury and demonstrate cardioprotection in isolated cardiomyocytes 9 ( Figure 1) . However, other cells can also contribute to cardiomyocyte cell death during reperfusion injury. This is particularly clear in the case of platelets, the activation and adhesion of which increase cell death independently of aggregation and of any effects on myocardial flow. 10 Activated resident cardiac fibroblasts may also exacerbate the local inflammatory reaction and aggravate reperfusion damage to cardiomyocytes. 11, 12 Microvascular injury and microvascular obstruction may prevent the restoration of myocardial blood flow despite restoration of coronary artery patency in patients with STEMI, and its extent is associated with larger MI size, adverse LV remodelling, 13 and worse prognosis, 14, 15 but up to what a point it is a cause or consequence of the existence of large infarcts needs to be clarified-and it may depend on the circumstances. Furthermore, increased endothelial permeability and subsequent recruitment of inflammatory cells into the site of infarction may also contribute to acute ischaemia/reperfusion injury-a number of clinical studies that have investigated antiinflammatory therapies administered at the time of reperfusion to reduce MI size have had neutral results. 16, 17 The mitochondrial permeability transition pore (MPTP) is an important mediator of myocardial reperfusion injury, 18 20 Reactive oxygen species may induce MPTP opening, and interventions attenuating mitochondrial ROS production can prevent MPTP opening and reduce MI size, 21 but they also have extra-mitochondrial targets, the importance of which needs to be clarified. A potentially important target of ROS is the tetrahydrobiopterin -eNOS complex, which may be dissociated by oxidation, resulting in peroxynitrite formation and reduced NO availability. 22 Recent studies have proposed that RIP3-mediated programmed cell necrosis may play a role in myocardial reperfusion injury through CaMKII and the MPTP. 23 A number of mechanical and pharmacological interventions have been investigated in clinical cardioprotection studies to target myocardial reperfusion injury in reperfused STEMI patients over the last few years-these are discussed in the following sections ( magnetic resonance imaging (MRI). 27, 28 Several, but not all, Phase II trials have confirmed that ischaemic post-conditioning (IPost) is cardioprotective in STEMI patients admitted with a full coronary artery occlusion. 29 -32 Reasons for failure of some trials might be related to the absence of direct stenting and delivery of the IPost protocol within the stent with the incumbent risk of coronary microembolization. 31 -33 Specific questions remain as to whether all patients may benefit from IPost given the potential influence of risk factors (e.g. diabetes, age) and concurrent treatments (e.g. anti-platelet agents, statins). 34 -38 Although none of these studies have reported safety concerns, it remains uncertain whether IPost can improve clinical outcomes in STEMI patients. In this regard, the DANAMI-3 Phase III trial has completed recruitment, and the results are expected this year (NCT01435408). 39 
Remote ischaemic conditioning
The application of cycles of brief ischaemia and reperfusion to an organ or tissue remote from the heart has been demonstrated to reduce MI size following an episode of acute ischaemia/reperfusion injury, a phenomenon which has been termed remote ischaemic conditioning (RIC). 40 -44 The ability to recapitulate this cardioprotective effect by simply inflating a blood pressure cuff placed on the upper arm or thigh to induce cycles of brief ischaemia and reperfusion in the upper or lower limb, has facilitated the translation of RIC into the clinical setting, where it has been shown to reduce perioperative myocardial injury but to not improve clinical outcomes in patients undergoing coronary artery bypass graft surgery. 45 -49 Several clinical studies have found that RIC using transient arm or leg ischaemia/reperfusion reduced MI size by 20 -30% (assessed by cardiac enzymes, SPECT or cardiac MRI) in STEMI patients reperfused by either PPCI 50 -54 or thrombolysis. 55 Furthermore, RIC has been reported to improve LV systolic function at four weeks in a subgroup of anterior STEMI patients 56 and reduce major adverse cardiac and cerebral events in a follow-up study of 251 STEMI patients. 57 It has been shown to be a cost-effective intervention within the first 2 years following PPCI, an effect which was mainly driven by a reduction in hospital re-admissions for heart failure (unpublished data). Finally, post hoc analysis failed to find any major confounding effects of co-morbidities or concomitant medication on the cardioprotective efficacy of RIC in reperfused STEMI patients. 58 In summary, RIC using transient limb ischaemia/reperfusion holds promise as an adjunct to PPCI in STEMI patients for reducing MI size. Whether it can improve long-term clinical outcomes is not known and is currently being investigated in the 4300 STEMI patient CONDI-2/ERIC-PPCI clinical study. 59 Therapies which target the nitric oxide/cyclic guanosine monophosphate signalling pathway Pre-clinical data shows consistent cardioprotection:
Potential issues over safety: 2, no known safety issues; +/2, potential safety issues.
Clinical MI studies: ++, several positive MI studies;
+, only one positive MI study;
neutral MI studies.
Meta-analysis data: +, positive data; +/2, inconsistent data.
Clinical outcome studies: *, outcome study ongoing; 2, neutral outcome study data.
Targeting reperfusion injury in STEMI patients size. 60 However, there is only one published trial testing the effect of stimulating cGMP synthesis by particulate guanylate cyclase with atrial natriuretic peptide in STEMI-it showed a modest reduction in enzymatic MI size. 61 A number of other clinical trials have investigated other therapies which target the NO/cGMP signalling pathway. These include insulin, as part of glucose -insulin -potassium (GIK) therapy which has had mixed results in clinical studies, although the IMMEDIATE trial found that GIK administered in the ambulance reduced MI size in a subset of STEMI patients, 62 and other insulin-mimetics such as exenatide.
Exenatide
The anti-diabetic, glucagon-like peptide-1 (GLP-1), has been demonstrated in experimental animal studies to reduce MI size when administered at the onset of reperfusion by mechanisms independent of increased insulin levels. 63 As a therapeutic strategy, the GLP-1 analogue, exenatide, has also been shown to protect against myocardial reperfusion injury in small and large animal MI models. 64, 65 In the clinical setting, an intravenous infusion of exenatide initiated prior to PPCI has been shown to reduce MI size in patients presenting with an acute STEMI, especially in those patients presenting with short ischaemic times from symptom onset (,132 min).
-68
Another GLP-1 analogue, liraglutide, when administered prior to PPCI and continued for 7 days, has been shown in a study of 85 STEMI patients to improve LV systolic function. 69 Further studies are now required to determine whether this therapeutic approach can improve clinical outcomes in reperfused STEMI patients.
Nitric oxide and nitrite
Nitric oxide is known to be an important mediator of cardioprotection in various forms of ischaemic conditioning, 70 and circulatory nitrite has been demonstrated to be a potential humoral mediator of remote ischaemic preconditioning. 71 Although, there have been experimental studies demonstrating cardioprotection with intravenous nitrite administered at the onset of reperfusion, 72 the National Heart Lung and Blood Institute (NHLBI) Consortium for preclinicAl assESsment of cARdioprotective therapies (CESAR) Network failed to demonstrate MI size reduction with nitrite using a multi-centre approach in small and large animal MI models. 73, 74 Two recent clinical studies have failed to demonstrate a significant reduction in MI size with nitrite administered by either the intravenous 75 or intracoronary 76 routes in STEMI patients treated by PPCI.
However, there was a borderline increase in myocardial salvage index and reduced MI size in a subgroup of patients presenting with a fully occluded coronary artery. 76 The recent 250 patient NOMI study (NCT01398384) has investigated the role of inhaled nitric oxide (vasoKINOX 450) as an adjunct to PPCI to target myocardial reperfusion injury in STEMI patients. Although no beneficial effect on MI size (Day 3 cardiac MRI) was demonstrated, post hoc subgroup analysis revealed that there was a significant reduction in MI size in those patients who had not received nitrates in the ambulance.
Since there were no adverse events in these trials, further studies on nitrite and nitric oxide appear worthwhile, to test whether this therapeutic approach may yield benefit in a selected patient group.
Cyclosporin A
As a potent inhibitor of MPTP opening, cyclosporin A (CsA) has been shown to significantly reduce MI size in a number of experimental studies, 77 -79 but not all. 80, 81 Some, but not all, Phase II clinical trials have suggested that CsA might also protect the heart and brain following a prolonged ischaemic insult. 82 -86 The recently completed CYCLE trial of 410 STEMI patients failed to demonstrate any benefit with CsA administered prior to PPCI in terms of ST-segment resolution and enzymatic MI size. 87 Finally, in the CsA in Reperfused Acute Myocardial Infarction (CIRCUS) 970 patient trial, the administration of CsA immediately prior to PPCI failed to improve clinical outcomes at 1 year (all-cause death, heart failure hospitalization, and adverse LV remodelling) in anterior STEMI patients. 1 Why these larger clinical trials failed to confirm the benefit of CsA in reducing MI size from initial Phase II trials is unclear. 88, 89 Apart from a classical type I error frequently observed in smallsize clinical studies, several different causes may have attributed to the neutral results of the CIRCUS trial: (i) CsA is a non-specific inhibitor of cyclophilin D and its other actions (e.g. cyclophilin A and calcineurin inhibition) might have counteracted the benefit of inhibiting MPTP opening. 90 (ii) Important changes in STEMI patients since the initial Phase II trial might have played a role, including a greater use of the new P 2 Y 12 platelet inhibitors (prasugrel, ticagrelor), which are known to reduce MI size per se. 91 (iii) The concentration of CsA required to inhibit MPTP opening in STEMI patients is not known. The blood concentration of CsA at 4 h after IV bolus administration averaged 533 + 189 ng/mL in a subset of CIRCUS patients-this was comparable to that observed in the original positive Phase II trial.
1,82 (iv) Whether it is enough to inhibit MPTP open-
ing to prevent myocardial reperfusion injury in STEMI patients may be questioned. One may wonder whether much longer ischaemia times observed in humans (when compared with animal models) might alter the binding site or the function of cyclophilin D and render it inaccessible to CsA. This last point may be pertinent in the CIRCUS trial in which total ischaemic times were relatively prolonged at 4.5 h. 1 In any case, the failure of CsA to improve clinical outcomes in STEMI patients by no means questions the concept of protection against myocardial reperfusion injury.
MTP-131
The mitochondria-targeting peptide, MTP-131, optimizes mitochondrial energetics and attenuates the production of ROS by selectively targeting cardiolipin in the inner mitochondrial membrane. It has been reported in small and large animal experimental studies to reduce MI size when administered at the onset of reperfusion and prevent adverse LV remodelling following MI. 92, 93 However, in the 117 patient EMBRACE STEMI clinical trial, 94 intravenous MTP-131 administered prior to PPCI failed to reduce enzymatic MI size in a carefully selected population of anterior STEMI patients with ischaemic time ,4 h, no collaterals, and fully occluded coronary artery. The reasons for the neutral results of this study are not known, but may include reasons similar to those of other MPTP-targeted interventions (as discussed previously) as well as pharmacokinetic or pharmacodynamic difficulties to target mitochondria in STEMI patients. Clinical trials are currently underway to investigate whether this agent can benefit patients with chronic heart failure.
TRO40303
The mitochondrial targeting drug, TRO40303, which binds to the translocator protein TSPO in the outer mitochondrial membrane and aims to inhibit MPTP opening by attenuating ROS production, has been reported in small animal experimental studies to reduce MI size when administered at time of reperfusion. 95 However, in a clinically-relevant large animal MI model, it failed to reduce MI size in the porcine heart. 96 In the 163 STEMI patient MITOCARE study, 97 this agent failed to reduce MI size despite careful patient selection (completely occluded infarct-related artery, large areaat-risk). Prior experimental studies had revealed ambiguous cardioprotective capacity, and the formulation and dosage of TRO40303 used in the clinical study differed from experimental studies, which may in part explain the neutral findings of the MITOCARE study. Finally, more adverse events were reported in patients receiving TRO40303 when compared with the placebo arm, 97 thereby limiting the clinical application of this therapeutic approach.
Protein kinase C-d inhibition
After Downey et al. first identified protein kinase C (PKC) to be a cytosolic mediator of ischaemic preconditioning protection, the role of the PKC-d isoform in cardioprotection has been contentious, 70 with some studies reporting its genetic 98 or pharmacological 99 inhibition to be cardioprotective, while other studies finding it to be a mediator of ischaemic preconditioning and opioid cardioprotection. 100, 101 An initial clinical study (DELTA-MI) 102 had suggested that intracoronary delcasertib administered prior to PPCI may be cardioprotective in STEMI patients. However, in the follow-up PROTECT-MI trial, delcasertib was given as an intravenous instead of intracoronary infusion and it failed to reduce MI size in acute anterior STEMI patients. 103 A number of factors may have contributed to the neutral results of the PROTECT AMI trial including inconsistent experimental data, inadequate dosing with the intravenous route of administration, and inclusion of patients who had spontaneously reperfused prior to PPCI. Therefore, as a therapeutic strategy, PKC-d inhibition appears to be limited in its clinical application.
Adenosine
The role of adenosine as a mediator of cardioprotection is wellestablished, 70 with experimental studies demonstrating that adenosine administered prior to index ischaemia can reduce MI size; however, whether it can also reduce MI size when administered at the time of reperfusion has been very contentious. 104, 105 Unsurprisingly then, the results of clinical studies investigating adenosine as an adjunct to PPCI have also been inconsistent, and this may, in part, relate to patient selection, the variable doses used, and the route of administration (intravenous vs. intracoronary). 106 Some studies have reported reductions in MI size with high-dose intravenous adenosine administered as a 3 h infusion initiated prior to reperfusion in STEMI patients presenting within 3 h of chest pain onset, 107 -109 with other studies using lower doses of IV adenosine or boluses of intracoronary adenosine being less successful at reducing MI size.
110
A recent meta-analysis has shown a positive effect of adenosine treatment on heart failure outcomes in reperfused STEMI patients. 106 Therefore, larger clinical trials are needed to test whether this therapeutic approach is effective in STEMI patients presenting with shorter ischaemic times.
Therapeutic hypothermia
Therapeutic hypothermia has been consistently shown to reduce MI size in pre-clinical studies. 111 Large animal experiments have shown Targeting reperfusion injury in STEMI patients that hypothermia dose-dependently down to 328C is cardioprotective if initiated during ischaemia but not after reperfusion. 112 -115 Even prolonged ischaemia to induce hypothermia has been noted to reduce MI size. 116 However, early clinical studies (ICE-IT, COOL-MI) failed to demonstrate a benefit of hypothermia, possibly due to slow cooling. 117, 118 Combination of cold saline and endovascular cooling induced a faster temperature fall and reduced MI size in a 20-patient pilot trial (RAPID MI-ICE), while the larger CHILL-MI trial failed to demonstrate a significant reduction in MI size, although patients presenting within 4 h with an anterior STEMI had a reduction in MI infarct size and there was also a significant reduction in heart failure rate. 119, 120 It is thought therefore that, in order to translate this therapeutic approach into the clinical setting, new devices capable of delivering faster cooling are needed. This possibility is currently being investigated in anterior STEMI patients in the COOL AMI EU Pilot Trial (NCT02509832), and newer techniques are being developed, which allow non-invasive rapid hypothermia to ,328C in 20 min to be initiated in the ambulance. 121 
Metoprolol
Intravenous metoprolol administered prior to reperfusion has been shown to reduce MI size and preserve LV systolic function in the porcine heart. 122 The mechanisms underlying this cardioprotective effect are currently being investigated and appear to extend beyond their effects on haemodynamics and myocardial oxygen consumption. In the 270 anterior STEMI patient METOCARD-CNIC trial, intravenous metoprolol administered in the ambulance prior to PPCI reduced MI size prevented LV adverse remodelling, preserved LV systolic function, and lowered hospital re-admissions for heart failure. 123, 124 Results are awaited from the EARLY BAMI trial, which has recently completed recruitment of 600 STEMI patients and which investigated the effect of IV metoprolol or placebo prior to PPCI on MI size by cardiac MRI. 125 However, this therapeutic approach may not be suitable for all STEMI, and those with heart failure, hypotensive, or presenting with AV block will not qualify for this therapy. Whether this therapeutic approach can improve clinical outcome in reperfused STEMI patients will be addressed by the MOVE ON! randomized clinical trial, which will investigate the effect of metoprolol on cardiac death and heart failure hospitalization.
Optimizing approaches to cardioprotection More rigorous selection of cardioprotective therapy
A number of clinical trials may have failed to demonstrate benefit with some cardioprotective therapies due to inconsistent and/or insufficient experimental data (see Figure 1) . In some cases, meta-analyses of experimental studies have been necessary to determine the efficacy of a particular treatment (see Figure 1) . Other treatments have been tested in clinical trials without prior experimental studies in large animals. In general, most interventions have been studied only in healthy, young animals, and pre-clinical studies in adult or older animals, with co-morbidities and concomitant medication usually received by patients with STEMI have been lacking. 38, 126 Among concomitant medication relevant to STEMI patients, platelet inhibitors may be particularly important, as they have been shown to have cardioprotective effects, 10,91 which may interfere with cardioprotective interventions. 127 In general, studies on novel cardioprotective therapies should be performed only in patients after consistent demonstration of efficacy and absence of safety concerns obtained in adequate small and large animal models in different laboratories using standardized methods. Research networks may be necessary to obtain the necessary level of pre-clinical evidence. In this regard, the NHLBI CESAR network was set up in the USA with this purpose in mind, 73, 128 and similar networks should be created in Europe.
Optimizing clinical study design
In some instances, the failure of some clinical trials may have been predictable based on issues related to clinical study design.
Patient selection
It is important to select the patients who have been shown in clinical studies who derive the most benefit from an intervention applied as an adjunct to PPCI to reduce MI size; this includes those STEMI patients presenting with the following: † Short ischaemic time (,2-3 h) 67 ,109 † Large area-at-risk (.30 -40% of LV) 129 such as anterior STEMI † Fully occluded coronary artery prior to PPCI (TIMI flow ,1)
† No significant coronary collaterals
Dosing the intervention A failure to ascertain the most efficacious dose of the cardioprotective intervention, whether it be a mechanical or pharmacological one, may have contributed to the failure to translate cardioprotection in some of the clinical STEMI studies.
Timing the intervention
The intervention is more likely to be effective at targeting myocardial reperfusion injury in the following circumstances: † There is consistent pre-clinical evidence that the intervention can reduce MI size when administered prior or at the onset of reperfusion, and it has achieved sufficient concentrations in the blood in the first few minutes of reperfusion. † It is important to note that those cardioprotective interventions that are effective only when present during the ischaemic period may act by reducing acute myocardial ischaemic injury. 62, 123 Limiting ischaemic injury is a very effective strategy to limit MI size, but it may be difficult to apply in STEMI because it requires very early administration, and in patients with a completely occluded artery, the treatment may not be able to reach the ischaemic myocardium. Even when drugs are administered before reperfusion, they may not reach a sufficient concentration in time to protect against the cell death, which occurs in the first few minutes of reflow.
Combination therapy for reducing myocardial infarct size
Using combination reperfusion therapy to target either the different pro-survival signalling pathways within the cardiomyocyte or 
Future perspectives
Translating cardioprotective therapies for targeting myocardial reperfusion injury from experimental studies into the clinical setting for patient benefit has been extremely challenging. The failure to find an effective agent for preventing myocardial reperfusion injury thus far, however, does not question the existence of myocardial reperfusion injury as a valid target for cardioprotection. Rather it underscores the need to better understand the mechanisms underlying myocardial reperfusion injury. As such experimental studies in this area should continue, as this will allow us to better define effective therapeutic strategies for targeting reperfusion injury to reduce MI size. Currently, an incomplete understanding and lack of appreciation of the complexities of myocardial reperfusion injury has contributed, in part, to the failure to effectively target myocardial reperfusion injury in the clinical setting for patient benefit. Clinical research in this area should also continue. However, lessons should be learned from recent clinical trials: (i) future clinical trials should be restricted to interventions with consistent experimental data and the latter should include studies in large animals; (ii) clinical study design is crucial when testing novel cardioprotective therapies in STEMI patients; and (iii) only interventions consistently found to be effective at limiting MI size in Phase II clinical trials should be investigated in large clinical outcome trials.
Therapeutic strategies that have potential to improve clinical outcomes in reperfused STEMI patients include remote ischaemic conditioning, exenatide, and metoprolol, and clinical studies are underway to test their efficacy in this regard. New approaches for limiting MI size should include combination therapy to (i) target different cardioprotective signalling pathways within the cardiomyocyte in order to provide additive cardioprotection and (ii) target the different players involved in myocardial reperfusion injury (cardiomyocyte, microvasculature, inflammatory cells, and platelets). These experimental and clinical studies are currently underway and should allow more effective targeting of myocardial reperfusion injury, thereby reducing MI size in reperfused STEMI and preventing the onset of heart failure. 
